Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

News Daily News

FDA Approves Two Generic Versions of Apixaban

December 23, 2019

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

News Features

Year in Review: Endovascular Saw Paclitaxel Storm Rage, CLI Care Advance in 2019

December 12, 2019

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

News Daily News

Switch Anticoagulants for A-fib Patients Needing a Stent? RE-DUAL PCI Insights

December 02, 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

News Conference News AHA 2019

Full GALILEO Results Confirm Harm With Rivaroxaban After TAVR

November 17, 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

November 11, 2019

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

News Daily News

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Michael O'Riordan

October 17, 2019

Bleeding Risk Similar for Peripheral, Coronary Revascularization: EUCLID

News Daily News

Bleeding Risk Similar for Peripheral, Coronary Revascularization: EUCLID

October 16, 2019

Rivaroxaban Falls Flat in Antiphospholipid Antibody Syndrome

News Daily News

Rivaroxaban Falls Flat in Antiphospholipid Antibody Syndrome

October 15, 2019

FDA Gives Rivaroxaban Another VTE-Related Indication

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

October 14, 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

News Conference News TCT 2019

Leaflet Thickening and Impaired Motion No Worse With TAVR: PARTNER 3 CT

Michael O'Riordan

September 27, 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

September 26, 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

News Daily News

Bleeding on Low-Dose Antithrombotic Therapy a ‘Red Flag’ for New Cancers

Yael L. Maxwell

September 20, 2019

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

September 20, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

September 03, 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

News Conference News ESC 2019

AFIRE Supports Rivaroxaban Monotherapy in A-fib Patients With Stable CAD

September 02, 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

News Conference News ESC 2019

Ticagrelor Risky in Diabetic Patients With Stable CAD: THEMIS

Michael O'Riordan

September 01, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.